<DOC>
	<DOCNO>NCT02802709</DOCNO>
	<brief_summary>This study evaluate novel agent , SB-061 , treatment osteoarthritis knee . Half patient receive agent via intra-articular injection half receive placebo injection .</brief_summary>
	<brief_title>A Trial SB-061 Osteoarthritis Knee</brief_title>
	<detailed_description>The treatment pain associate osteoarthritis may include periodic intra-articular injection corticosteroid viscosupplements hyaluronic acid . SB-061 anticipated relieve osteoarthritis pain reinforce cartilage matrix provide lubricate coating cartilage . Subjects receive 2 intra-articular injection either SB-061 placebo follow 3 month evaluate pain amelioration . Subjects Investigators blind treatment allocation .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Femorotibial osteoarthritis knee Radiological OA KellgrenLawrence grade 2 3 WOMAC Pain 1 score target knee ≥4 ≤ 9 Hypersensitivity medication intraarticular injection Intraarticular delivery corticosteroid hyaluronic acid target knee within 6 month study High dose systemic corticosteroid treatment longer ( &gt; 14 day ) duration w/in 6 month study Major surgery arthroscopy target knee within year prior study Planned surgery target knee within next 3 month Concomitant inflammatory disease affect either knee</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>knee</keyword>
</DOC>